NZ703321A - Risperidone or paliperidone implant formulation - Google Patents

Risperidone or paliperidone implant formulation

Info

Publication number
NZ703321A
NZ703321A NZ703321A NZ70332113A NZ703321A NZ 703321 A NZ703321 A NZ 703321A NZ 703321 A NZ703321 A NZ 703321A NZ 70332113 A NZ70332113 A NZ 70332113A NZ 703321 A NZ703321 A NZ 703321A
Authority
NZ
New Zealand
Prior art keywords
risperidone
range
kda
lactic
molecular weight
Prior art date
Application number
NZ703321A
Other languages
English (en)
Inventor
Aduriz Ibon Gutierro
Rodríguez Guillermo Franco
Original Assignee
Laboratorios Farmacéuticos Rovi S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46147376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ703321(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Farmacéuticos Rovi S A filed Critical Laboratorios Farmacéuticos Rovi S A
Publication of NZ703321A publication Critical patent/NZ703321A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ703321A 2012-05-31 2013-05-31 Risperidone or paliperidone implant formulation NZ703321A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170362.3A EP2529756B1 (en) 2011-05-31 2012-05-31 Risperidone and/or Paliperidone implant formulation
PCT/EP2013/061320 WO2013178812A1 (en) 2012-05-31 2013-05-31 Risperidone or paliperidone implant formulation

Publications (1)

Publication Number Publication Date
NZ703321A true NZ703321A (en) 2017-01-27

Family

ID=46147376

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ703321A NZ703321A (en) 2012-05-31 2013-05-31 Risperidone or paliperidone implant formulation

Country Status (32)

Country Link
EP (2) EP2529756B1 (https=)
JP (1) JP6367795B2 (https=)
KR (1) KR101880716B1 (https=)
CN (1) CN104363923A (https=)
AU (1) AU2013269547B2 (https=)
BR (1) BR112014029209A2 (https=)
CA (1) CA2874765C (https=)
CL (1) CL2014003216A1 (https=)
CO (1) CO7160108A2 (https=)
CY (1) CY1124369T1 (https=)
DK (2) DK2529756T3 (https=)
EA (1) EA031819B1 (https=)
ES (1) ES2878112T3 (https=)
FI (1) FI2854858T3 (https=)
HR (2) HRP20260301T1 (https=)
IL (1) IL235849B (https=)
IN (1) IN2014DN10672A (https=)
LT (2) LT2529756T (https=)
MA (1) MA37664B1 (https=)
MX (1) MX374955B (https=)
MY (1) MY174999A (https=)
NZ (1) NZ703321A (https=)
PH (1) PH12014502667B1 (https=)
PL (2) PL2529756T3 (https=)
PT (2) PT2529756T (https=)
RS (1) RS62059B1 (https=)
SG (1) SG11201407961WA (https=)
SI (1) SI2529756T1 (https=)
SM (1) SMT202100448T1 (https=)
UA (1) UA119430C2 (https=)
WO (1) WO2013178812A1 (https=)
ZA (1) ZA201409299B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
EP2529757B1 (en) * 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
LT2394664T (lt) 2010-05-31 2016-09-26 Laboratorios Farmaceuticos Rovi, S.A. Antipsichozinė injekcinė depozitinė kompozicija
PT2394663T (pt) 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
LT2529756T (lt) * 2011-05-31 2021-07-26 Laboratorios Farmaceuticos Rovi, S.A. Risperidono ir (arba) paliperidono implantų kompozicija
HK1220628A1 (zh) 2013-03-11 2017-05-12 Durect Corporation 包含高粘度液体载体的可注射控制释放组合物
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
CN104922085B (zh) * 2015-06-01 2016-10-26 湖南赛沃药业有限公司 一种利培酮植入剂及其制备方法
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
US11689849B2 (en) 2018-05-24 2023-06-27 Nureva, Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
AU2023281232A1 (en) 2022-05-18 2024-10-24 Laboratorios Farmacéuticos Rovi, S.A. Prolonged-release injectable compositions for use in treatment with risperidone together with cyp2d6 enzyme inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074923C (zh) 1993-11-19 2001-11-21 詹森药业有限公司 微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
WO2005007122A2 (en) * 2003-07-18 2005-01-27 Oakwood Laboratories, L.L.C. Polymer stabilization
JP2008509144A (ja) 2004-08-04 2008-03-27 アルザ・コーポレーシヨン 上昇するゼロ次放出パターンを示す持続薬剤放出組成物、そのような組成物を製造する方法
JP5315336B2 (ja) 2007-04-19 2013-10-16 又欣 李 精神疾患治療用の新規化合物とその調剤及び使用
DK2167039T3 (en) * 2007-05-18 2017-01-09 Durect Corp Improved depot formulations
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
WO2009015828A1 (en) 2007-07-27 2009-02-05 Synthon B.V. Paliperidone derivatives
BRPI0821408A2 (pt) 2007-12-19 2015-06-16 Janssen Pharmaceutica Nv Regime de dosagem associado a ésteres de paliperidona injetáveis de longa ação
EP2485712A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
EP2529757B1 (en) * 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
LT2394664T (lt) 2010-05-31 2016-09-26 Laboratorios Farmaceuticos Rovi, S.A. Antipsichozinė injekcinė depozitinė kompozicija
PT2394663T (pt) * 2010-05-31 2021-11-26 Farm Rovi Lab Sa Composições para implantes biodegradáveis injectáveis
LT2529756T (lt) * 2011-05-31 2021-07-26 Laboratorios Farmaceuticos Rovi, S.A. Risperidono ir (arba) paliperidono implantų kompozicija

Also Published As

Publication number Publication date
CA2874765A1 (en) 2013-12-05
JP6367795B2 (ja) 2018-08-01
ZA201409299B (en) 2015-12-23
SI2529756T1 (sl) 2021-09-30
PH12014502667B1 (en) 2020-01-22
HRP20260301T1 (hr) 2026-04-10
SG11201407961WA (en) 2014-12-30
IN2014DN10672A (https=) 2015-08-28
BR112014029209A2 (pt) 2017-06-27
PT2529756T (pt) 2021-07-28
EA031819B1 (ru) 2019-02-28
HRP20211057T1 (hr) 2021-10-01
PH12014502667A1 (en) 2015-02-02
KR20150016964A (ko) 2015-02-13
CY1124369T1 (el) 2022-07-22
MX374955B (es) 2025-03-06
CN104363923A (zh) 2015-02-18
LT2529756T (lt) 2021-07-26
CL2014003216A1 (es) 2015-07-10
EP2529756A3 (en) 2013-08-07
EP2854858B1 (en) 2025-12-10
CO7160108A2 (es) 2015-01-15
EA201401346A1 (ru) 2015-04-30
RS62059B1 (sr) 2021-07-30
PL2854858T3 (pl) 2026-04-20
AU2013269547B2 (en) 2018-03-15
CA2874765C (en) 2020-06-02
AU2013269547A1 (en) 2015-01-22
DK2529756T3 (da) 2021-08-02
IL235849B (en) 2019-03-31
EP2529756B1 (en) 2021-05-19
MY174999A (en) 2020-06-01
EP2529756A2 (en) 2012-12-05
MA37664B1 (fr) 2016-11-30
WO2013178812A1 (en) 2013-12-05
KR101880716B1 (ko) 2018-08-17
UA119430C2 (uk) 2019-06-25
SMT202100448T1 (it) 2021-09-14
PL2529756T3 (pl) 2021-11-15
EP2854858A1 (en) 2015-04-08
MX2014014483A (es) 2015-02-24
IL235849A0 (en) 2015-01-29
PT2854858T (pt) 2026-03-06
FI2854858T3 (fi) 2026-03-03
LT2854858T (lt) 2026-03-10
MA37664A1 (fr) 2016-03-31
ES2878112T3 (es) 2021-11-18
JP2015518036A (ja) 2015-06-25
DK2854858T3 (da) 2026-03-09

Similar Documents

Publication Publication Date Title
NZ703321A (en) Risperidone or paliperidone implant formulation
PH12014502668A1 (en) Paliperidone implant formulation
Thakur et al. Solvent induced phase inversion-based in situ forming controlled release drug delivery implants
WO2012166923A3 (en) Drug loaded polymeric nanoparticles and methods of making and using same
MX346167B (es) Procedimientos para la preparacion de composiciones inyectables de liberacion controlada.
CL2016002836A1 (es) Compuestos derivados de pirido pirimidin con actividad moduladora del empalme genico de smn2; composicion farmaceutica y uso en el tratamiento de la atrofia muscular espinal (ame).
NZ607797A (en) Corticosteroids for the treatment of joint pain
WO2010005723A3 (en) Drug loaded polymeric nanoparticles and methods of making and using same
EP2853543A8 (en) Anti-blys antibody
ME02501B (me) Antipsihoticka injektabilna deponujuca kompozicija
SA517381298B1 (ar) تركيبة صيدلية بثبات محسن
MY189110A (en) Fast acting orally disintegrating film
WO2016040814A3 (en) Disulfide polymers and methods of use
BR112015011294A8 (pt) nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas
WO2014127232A3 (en) Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
EP4566638A3 (en) Implant for treatment of an ocular condition
WO2009148583A3 (en) Method for improvement of octreotide bioavailability
HK1255848A1 (zh) 用於关节内浸润疗法的可注射液体组合物
Gavard An innovative hyaluronic acid product for viscosupplementation in patients with osteoarthritis
TH159015A (th) ริสเพอริโดนหรือสูตรตำรับในการปลูกถ่ายพาลิเพอริโดน
WO2015161841A3 (de) Injizierbare und implantierbare trägersysteme auf basis von modifizierten poly(dikarbonsäure-polyol estern) zur kontrollierten wirkstofffreisetzung
UA106582U (uk) Спосіб профілактики післяопераційного делірію у пацієнтів похилого віку
HK1195285A (en) Post electron beam conditioning of polymeric medical devices

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAY 2018 BY AJ PARK

Effective date: 20170526

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAY 2019 BY AJ PARK

Effective date: 20180427

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAY 2020 BY DENNEMEYER + CO.

Effective date: 20190419

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAY 2021 BY PETRA OLK

Effective date: 20200519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAY 2022 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20210526

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAY 2023 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20220523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAY 2024 BY DENNEMEYER + CO.

Effective date: 20230522

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAY 2025 BY DENNEMEYER + CO. S.A R.L.

Effective date: 20240523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 MAY 2026 BY DENNEMEYER + CO. SARL

Effective date: 20250519